Amarin Co. plc (NASDAQ:AMRN) Shares Bought by LCM Capital Management Inc

LCM Capital Management Inc grew its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 5.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 740,159 shares of the biopharmaceutical company’s stock after acquiring an additional 36,000 shares during the quarter. LCM Capital Management Inc owned about 0.18% of Amarin worth $644,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 34,725 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amarin by 16.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 17,613 shares during the period. SVB Wealth LLC boosted its holdings in Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 30,000 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in Amarin by 35.7% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 170,670 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Amarin by 18.9% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 20,500 shares during the period. Institutional investors and hedge funds own 22.25% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $1.08.

Amarin Stock Up 5.0 %

NASDAQ AMRN traded up $0.04 during trading hours on Tuesday, hitting $0.92. The company had a trading volume of 1,180,962 shares, compared to its average volume of 1,926,650. Amarin Co. plc has a fifty-two week low of $0.65 and a fifty-two week high of $1.49. The business has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $0.94. The firm has a market cap of $378.19 million, a P/E ratio of -6.58 and a beta of 1.98.

Amarin (NASDAQ:AMRN) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $74.71 million for the quarter, compared to analyst estimates of $72.46 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. Equities analysts forecast that Amarin Co. plc will post -0.14 EPS for the current fiscal year.

Amarin Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.